#United States #New York #Securities Fraud #Rosen Law Firm #Reckitt Benckiser

Reckitt Benckiser Group PLC: Investors Invited to Join Securities Fraud Class Action

Background of the Case

The Rosen Law Firm recently announced significant opportunities for investors who purchased American Depositary Shares (ADSs) of Reckitt Benckiser Group PLC (Ticker: RBGLY) during a defined period. Specifically, those who acquired shares between January 13, 2021, and July 28, 2024, and feel they may have been misled, are encouraged to consider their participation in a class action lawsuit.

This class action, which targets alleged securities fraud practices by the company, has been set into motion by concerns surrounding Reckitt Benckiser's conduct related to their infant formula product, Enfamil. It has been reported that the company did not disclose essential information regarding the increased risk of necrotizing enterocolitis (NEC) among premature infants due to the consumption of Enfamil, potentially affecting sales and exposing the company to substantial legal liabilities.

Important Deadlines

Investors are reminded of a critical deadline: August 4, 2025. By this date, those interested in serving as lead plaintiffs must take action. A lead plaintiff represents the collective interests of all class members and directs the litigation. Legal action can be joined through the Rosen Law Firm's designated site or via direct contact with their offices.

How To Participate

The Rosen Law Firm emphasizes that individuals can engage in this class action without incurring personal expenses thanks to their contingency fee arrangement. Prospective participants are encouraged to visit the firm's website for more information. Alternatively, they can reach Phillip Kim, Esq., toll-free at 866-767-3653 or contact him at phillip.kim@rosenlegal.com.

Why Rosen Law Firm?

The Rosen Law Firm prides itself on its extensive experience and track record in handling securities class actions. With significant settlements achieved for investors historically, including being ranked No. 1 by ISS Securities Class Action Services in terms of securities class action settlements, the firm advocates for the rights of shareholders globally. Laurence Rosen, the founding partner, has also received accolades from prominent legal publications citing him as a leader in the plaintiffs' bar.

Case Details

The allegations state that Reckitt Benckiser made material misrepresentations and omissions that likely led to investor losses. Failure to disclose the risks associated with their Enfamil formula not only misled consumers but also jeopardized their financial standing as more investors became aware of the potential legal fallout. The Rosen Law Firm asserts that as the truth about Reckitt's practices surfaced, investors suffered damages that warrant compensation.

Further Information

To remain updated, interested parties can connect with Rosen Law Firm through their social media platforms on LinkedIn, Twitter, and Facebook, where they post continuing updates relevant to the case and investor rights.

It is vital that investors remain informed about their rights and potential recovery actions. Those affected by Reckitt's alleged practices have the opportunity to take significant steps toward pursuing justice in light of these serious claims. This class action could be a pivotal moment for shareholders hoping to recover funds lost due to purportedly deceptive practices by Reckitt Benckiser.

Conclusion

The deadline for participating in this crucial legal action is approaching, and Reckitt Benckiser investors are urged to act decisively as the window for leading the claim closes on August 4, 2025. By joining together in this legal pursuit, affected shareholders can advocate for accountability and transparency within Reckitt Benckiser Group PLC, shielding their investment interests and fostering responsible corporate governance for the future.